Frequencies of multi- or trilineage dysplasia in AML as published in large studies in comparison with our data
Author . | No. of patients . | MLD (%) . | TLD (%) . | History of AML . |
---|---|---|---|---|
Brito-Bapapulle et al6 | 160 | — | 15 | de novo |
Guasgen et al7 | 336 | — | 12 | de novo |
Kariyama et al12 | 230 | — | 17 | de novo |
Ballen et al15 | 106 | — | 9 | All types |
Kariyama et al13 | 545 | — | 17 | de novo |
Haferlach et al16 | 609 | 25 | 15 | de novo |
Arber et al14 | 300 | 38 | — | All types |
Miyazaki et al17 | 559 | — | 28 | de novo |
Our study | 1766 | 30 | 9 | All types |
Author . | No. of patients . | MLD (%) . | TLD (%) . | History of AML . |
---|---|---|---|---|
Brito-Bapapulle et al6 | 160 | — | 15 | de novo |
Guasgen et al7 | 336 | — | 12 | de novo |
Kariyama et al12 | 230 | — | 17 | de novo |
Ballen et al15 | 106 | — | 9 | All types |
Kariyama et al13 | 545 | — | 17 | de novo |
Haferlach et al16 | 609 | 25 | 15 | de novo |
Arber et al14 | 300 | 38 | — | All types |
Miyazaki et al17 | 559 | — | 28 | de novo |
Our study | 1766 | 30 | 9 | All types |
MLD (multilineage dysplasia) indicates dysplastic features in 2 or 3 lineages according to WHO classification; TLD (trilineage dysplasia) dysplastic features in 3 lineages; —, no data.